Recovery from anti-recombinant-human-erythropoietin associated pure red cell aplasia in end-stage renal disease patients after renal transplantation.
Praditpornsilpa
Kearkiat
K
Division of Nephrology, Department of Medicine, Faculty of Medicine, Chulalongkorn University Hospital, Bangkok, Thailand. kearkiat@hotmail.com
Buranasot
Somphon
S
Bhokaisuwan
Narudee
N
Avihingsanon
Yingyos
Y
Pisitkul
Trairak
T
Kansanabuch
Talerngsak
T
Eiam-Ong
Somchai
S
Chusil
Sauwaluck
S
Intarakumtornchai
Tanin
T
Tungsanga
Kriang
K
D000293:Adolescent; D000328:Adult; D000906:Antibodies / Q000502:physiology; D004921:Erythropoietin / Q000009:adverse effects* / Q000276:immunology; D006397:Hematinics / Q000009:adverse effects* / Q000276:immunology; D006801:Humans; D007676:Kidney Failure, Chronic / Q000601:surgery*; D016030:Kidney Transplantation; D008875:Middle Aged; D011994:Recombinant Proteins; D012010:Red-Cell Aplasia, Pure / Q000139:chemically induced* / Q000628:therapy*; D012074:Remission Induction / Q000379:methods
D000906:Antibodies; D006397:Hematinics; D011994:Recombinant Proteins; D004921:Erythropoietin